The current status of checkpoint inhibitors in metastatic bladder cancer
For many decades, no significant improvements could be achieved to prolong the survival in metastatic bladder cancer. Recently, systemic immunotherapy with checkpoint inhibitors (anti-PD-L1/anti-CTLA-4) has been introduced as a novel treatment modality for patients with metastatic bladder cancer. We...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Verlag
2016
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/52960/1/The%20current%20status%20of%20checkpoint%20inhibitors%20in%20metastatic%20bladder%20cancer.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|